Baird Capital closes $185M technology, healthcare fund

Venture firm Baird Capital exceeded the target for its fourth fund by $25 million, closing with a total of $185 million in committed capital. Baird invests in technology-enabled services companies as well as those across the healthcare spectrum including diagnostics and medical devices. It has already invested some of the new fund in five companies including Catalyze, a company working on bringing cloud computing technology into the healthcare market and NeuMoDx Molecular, in vitro molecular diagnostic testing company. Baird's Venture Capital team commits about $10 to $15 million to a company throughout an investment period. The fund partners with companies that have strong, experienced management teams with capital efficient business models that show high promise to promote differentiated products or services necessary in their markets. Release

Suggested Articles

They say you are what you eat, but scientists at Rice University and the University of Washington may be taking that maxim a step further.

Acutus secured $170 million after acquiring a catheter developer and announcing a slew of new partnerships in arrhythmia treatment and monitoring.

Tangen Biosciences, developers of cheap and portable molecular diagnostics for outside the lab, has raised $9 million to kick off its VC efforts.